SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1050 participants.

Also called NCT07105917

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,050 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07105917
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07105917. Randomized; single masking; primary purpose treatment. Start 2025-08-01 (anticipated); primary completion 2026-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
SGLT-2 inhibitors
Intervention (Other)
Standard medical treatment
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07105917
Content hash
90bd71af8c8cdfc5df07b7c95032e65aa5f41b1953505d8be69db871daa2bc2b